Report cover image

Human Blood Products Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 129 Pages
SKU # APRC20352123

Description

Summary

According to APO Research, The global Human Blood Products market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Human Blood Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Blood Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Blood Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Human Blood Products include Biotest, BPL, CSL, Grifols, Kedrion, KM Biologics, LFB Group, Octapharma and Boya Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Blood Products, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Blood Products.
The Human Blood Products market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Blood Products market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Human Blood Products Segment by Company

Biotest
BPL
CSL
Grifols
Kedrion
KM Biologics
LFB Group
Octapharma
Boya Bio
Hualan Bio
Nanyue Bio
RAAS
Shuanglin Bio
CBPO
Tiantan Bio
Weiguang Bio
Takeda
Yuanda Shuyang
Human Blood Products Segment by Type

Immune Globulin
Coagulation Factor
Albumin
Other
Human Blood Products Segment by Application

Hospital
Retail Pharmacy
Other
Human Blood Products Segment by Application

Hospital
Retail Pharmacy
Other
Human Blood Products Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Blood Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Blood Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Blood Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Blood Products companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

129 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Human Blood Products by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Immune Globulin
2.2.3 Coagulation Factor
2.2.4 Albumin
2.2.5 Other
2.3 Human Blood Products by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Human Blood Products Breakdown Data by Type
3.1 Global Human Blood Products Historic Market Size by Type (2020-2025)
3.2 Global Human Blood Products Forecasted Market Size by Type (2026-2031)
4 Human Blood Products Breakdown Data by Application
4.1 Global Human Blood Products Historic Market Size by Application (2020-2025)
4.2 Global Human Blood Products Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Human Blood Products Market Perspective (2020-2031)
5.2 Global Human Blood Products Growth Trends by Region
5.2.1 Global Human Blood Products Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Human Blood Products Historic Market Size by Region (2020-2025)
5.2.3 Human Blood Products Forecasted Market Size by Region (2026-2031)
5.3 Human Blood Products Market Dynamics
5.3.1 Human Blood Products Industry Trends
5.3.2 Human Blood Products Market Drivers
5.3.3 Human Blood Products Market Challenges
5.3.4 Human Blood Products Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Human Blood Products Players by Revenue
6.1.1 Global Top Human Blood Products Players by Revenue (2020-2025)
6.1.2 Global Human Blood Products Revenue Market Share by Players (2020-2025)
6.2 Global Human Blood Products Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Human Blood Products Head Office and Area Served
6.4 Global Human Blood Products Players, Product Type & Application
6.5 Global Human Blood Products Manufacturers Established Date
6.6 Global Human Blood Products Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Human Blood Products Market Size (2020-2031)
7.2 North America Human Blood Products Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Human Blood Products Market Size by Country (2020-2025)
7.4 North America Human Blood Products Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Human Blood Products Market Size (2020-2031)
8.2 Europe Human Blood Products Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Human Blood Products Market Size by Country (2020-2025)
8.4 Europe Human Blood Products Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Human Blood Products Market Size (2020-2031)
9.2 Asia-Pacific Human Blood Products Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Human Blood Products Market Size by Country (2020-2025)
9.4 Asia-Pacific Human Blood Products Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Human Blood Products Market Size (2020-2031)
10.2 South America Human Blood Products Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Human Blood Products Market Size by Country (2020-2025)
10.4 South America Human Blood Products Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Human Blood Products Market Size (2020-2031)
11.2 Middle East & Africa Human Blood Products Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Human Blood Products Market Size by Country (2020-2025)
11.4 Middle East & Africa Human Blood Products Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Biotest
12.1.1 Biotest Company Information
12.1.2 Biotest Business Overview
12.1.3 Biotest Revenue in Human Blood Products Business (2020-2025)
12.1.4 Biotest Human Blood Products Product Portfolio
12.1.5 Biotest Recent Developments
12.2 BPL
12.2.1 BPL Company Information
12.2.2 BPL Business Overview
12.2.3 BPL Revenue in Human Blood Products Business (2020-2025)
12.2.4 BPL Human Blood Products Product Portfolio
12.2.5 BPL Recent Developments
12.3 CSL
12.3.1 CSL Company Information
12.3.2 CSL Business Overview
12.3.3 CSL Revenue in Human Blood Products Business (2020-2025)
12.3.4 CSL Human Blood Products Product Portfolio
12.3.5 CSL Recent Developments
12.4 Grifols
12.4.1 Grifols Company Information
12.4.2 Grifols Business Overview
12.4.3 Grifols Revenue in Human Blood Products Business (2020-2025)
12.4.4 Grifols Human Blood Products Product Portfolio
12.4.5 Grifols Recent Developments
12.5 Kedrion
12.5.1 Kedrion Company Information
12.5.2 Kedrion Business Overview
12.5.3 Kedrion Revenue in Human Blood Products Business (2020-2025)
12.5.4 Kedrion Human Blood Products Product Portfolio
12.5.5 Kedrion Recent Developments
12.6 KM Biologics
12.6.1 KM Biologics Company Information
12.6.2 KM Biologics Business Overview
12.6.3 KM Biologics Revenue in Human Blood Products Business (2020-2025)
12.6.4 KM Biologics Human Blood Products Product Portfolio
12.6.5 KM Biologics Recent Developments
12.7 LFB Group
12.7.1 LFB Group Company Information
12.7.2 LFB Group Business Overview
12.7.3 LFB Group Revenue in Human Blood Products Business (2020-2025)
12.7.4 LFB Group Human Blood Products Product Portfolio
12.7.5 LFB Group Recent Developments
12.8 Octapharma
12.8.1 Octapharma Company Information
12.8.2 Octapharma Business Overview
12.8.3 Octapharma Revenue in Human Blood Products Business (2020-2025)
12.8.4 Octapharma Human Blood Products Product Portfolio
12.8.5 Octapharma Recent Developments
12.9 Boya Bio
12.9.1 Boya Bio Company Information
12.9.2 Boya Bio Business Overview
12.9.3 Boya Bio Revenue in Human Blood Products Business (2020-2025)
12.9.4 Boya Bio Human Blood Products Product Portfolio
12.9.5 Boya Bio Recent Developments
12.10 Hualan Bio
12.10.1 Hualan Bio Company Information
12.10.2 Hualan Bio Business Overview
12.10.3 Hualan Bio Revenue in Human Blood Products Business (2020-2025)
12.10.4 Hualan Bio Human Blood Products Product Portfolio
12.10.5 Hualan Bio Recent Developments
12.11 Nanyue Bio
12.11.1 Nanyue Bio Company Information
12.11.2 Nanyue Bio Business Overview
12.11.3 Nanyue Bio Revenue in Human Blood Products Business (2020-2025)
12.11.4 Nanyue Bio Human Blood Products Product Portfolio
12.11.5 Nanyue Bio Recent Developments
12.12 RAAS
12.12.1 RAAS Company Information
12.12.2 RAAS Business Overview
12.12.3 RAAS Revenue in Human Blood Products Business (2020-2025)
12.12.4 RAAS Human Blood Products Product Portfolio
12.12.5 RAAS Recent Developments
12.13 Shuanglin Bio
12.13.1 Shuanglin Bio Company Information
12.13.2 Shuanglin Bio Business Overview
12.13.3 Shuanglin Bio Revenue in Human Blood Products Business (2020-2025)
12.13.4 Shuanglin Bio Human Blood Products Product Portfolio
12.13.5 Shuanglin Bio Recent Developments
12.14 CBPO
12.14.1 CBPO Company Information
12.14.2 CBPO Business Overview
12.14.3 CBPO Revenue in Human Blood Products Business (2020-2025)
12.14.4 CBPO Human Blood Products Product Portfolio
12.14.5 CBPO Recent Developments
12.15 Tiantan Bio
12.15.1 Tiantan Bio Company Information
12.15.2 Tiantan Bio Business Overview
12.15.3 Tiantan Bio Revenue in Human Blood Products Business (2020-2025)
12.15.4 Tiantan Bio Human Blood Products Product Portfolio
12.15.5 Tiantan Bio Recent Developments
12.16 Weiguang Bio
12.16.1 Weiguang Bio Company Information
12.16.2 Weiguang Bio Business Overview
12.16.3 Weiguang Bio Revenue in Human Blood Products Business (2020-2025)
12.16.4 Weiguang Bio Human Blood Products Product Portfolio
12.16.5 Weiguang Bio Recent Developments
12.17 Takeda
12.17.1 Takeda Company Information
12.17.2 Takeda Business Overview
12.17.3 Takeda Revenue in Human Blood Products Business (2020-2025)
12.17.4 Takeda Human Blood Products Product Portfolio
12.17.5 Takeda Recent Developments
12.18 Yuanda Shuyang
12.18.1 Yuanda Shuyang Company Information
12.18.2 Yuanda Shuyang Business Overview
12.18.3 Yuanda Shuyang Revenue in Human Blood Products Business (2020-2025)
12.18.4 Yuanda Shuyang Human Blood Products Product Portfolio
12.18.5 Yuanda Shuyang Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.